Radia Haroun

Learn More
analysis was to develop two cost effectiveness models taking into account the new management of the treatment of AF and VTE in France. The clinical and cost benefits of VKA (with/without the use of a PAS) has been evaluated versus new oral anticoagulants (NOAC): dabigatran, rivaroxaban and apixaban. Methods: A Markov model was built for the treatment of AF(More)
  • 1